GLP-1 medications reduced the risk of major adverse cardiovascular events by 13% compared to a placebo, according to a study published Nov. 25 in The Lancet Diabetes & Endocrinology.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
